$OCGN let me sum up the earnings call for you: Revenue - $0 Profit - $0 Loss - whatever our operating expenses are OCU310 - failed stage 3 trial OCU300 - still waiting on results, first half of 2020 now OCU400s - still preclinical, maybe next year NeoCart - still closing the deal but it’s not approved for market so who really cares? Buyback - soon as we get the Neocart cash There is nothing inherently wrong with this company other than the failed phase 3... it’s just people are expecting too much out of them in the near future and that’s just not going to happen. The 4 ODDs are positive and will help them make money long term but they are NOT a fast track. Stop pumping... that is done here. Now it’s just like any other biotech.
  • 1
  • 7